A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration
Article first published online: 16 JAN 2006
Copyright © 2006 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 21, Issue 2, pages 171–179, February 2006
How to Cite
Ritchie, C. W., Chiu, E., Harrigan, S., Macfarlane, S., Mastwyk, M., Halliday, G., Hustig, H., Hall, K., Hassett, A., O'Connor, D. W., Opie, J., Nagalingam, V., Snowdon, J. and Ames, D. (2006), A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. Int. J. Geriat. Psychiatry, 21: 171–179. doi: 10.1002/gps.1446
- Issue published online: 27 JAN 2006
- Article first published online: 16 JAN 2006
- Manuscript Accepted: 16 AUG 2005
- Manuscript Received: 24 MAY 2005
- Eli Lilly (Australia)
- clinical trial;
- quality of life
Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effects.
To determine whether either olanzapine or risperidone was superior in terms of efficacy or side effects when treating schizophrenia in late life.
Psychiatric symptoms, side effects and quality of life were rated every six weeks for 24 weeks of open label comparative treatment using standard measures. Group differences were examined using analysis of covariance and within-group changes over time were assessed using paired t-tests.
There were 34 olanzapine and 32 risperidone patients who entered the study, but intention to treat data was only available for 61 of the 66 patients. There were no clinical or demographic differences between the groups. Parkinsonism, positive and negative symptoms of schizophrenia improved in both groups both from baseline switch to olanzapine or risperidone and during the six month follow-up after completion of crossover. No significant differences were seen between groups on most measures. However, patients treated with olanzapine showed a significantly greater improvement in quality of life from baseline compared to risperidone patients.
Both drugs were well tolerated and their use was associated with fewer symptoms of schizophrenia and less adverse effects than were seen when the patients were taking a typical antipsychotic at baseline. Olanzapine appears to have particular benefit with regard to quality of life. Copyright © 2006 John Wiley & Sons, Ltd.